NASH: State of the Science, Epidemiology, Pathophysiology, and Natural History

In this downloadable slideset, Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP, reviews the science of NASH and its current diagnosis.
Format: Microsoft PowerPoint (.ppt)
File Size: 921 KB
Released: October 26, 2017

Acknowledgements

Supported by an educational grant from
Gilead Sciences, Inc.

Related Content

CCO commentary from Steven L. Flamm, MD, on the importance of screening patients with chronic HBV infection for hepatocellular carcinoma

Steven L. Flamm, MD Released: June 16, 2020

Hear CCO faculty Philip Newsome discuss the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Philip N. Newsome, PhD, FRCPE Released: February 12, 2020

CCO faculty Dr Juan Frias discusses the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Juan Pablo Frias, MD, FACE Released: February 5, 2020

Juan Frias and Philip Newsome: Learn about the agents in phase II and III clinical trials and their potential use in treatment.

Juan Pablo Frias, MD, FACE Philip N. Newsome, PhD, FRCPE Released: January 28, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue